Gadobutrol pharmacokinetic and safety study in pediatric subjects aged <2 years (term newborn infants to toddlers 23 months of age inclusive)

To evaluate the pharmacokinetics of gadobutrol in plasma at the standard dose of 0.1 mmol/kg body weight in pediatric subjects aged <2 years.

Pediatric subjects aged <2 years (term newborn infants to toddlers 23 months of age inclusive) scheduled to undergo routine gadolinium-enhanced MRI of any body region